By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.
La voix des personnes atteintes d'un cancer du sein
Médias
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2015
- 2014
- 2013
Our Journal Articles
Al, P., Hey, S., Weijer, C., Gillies, K., McCleary, N., Yee, M. L., Inglis, J., Presseau, J., & Brehaut, J. (2023). Changing patient preferences toward better trial recruitment: an ethical analysis. Trials, 24(1), 233. https://doi.org/10.1186/s13063-023-07258-4
Seung, S.J., Saherawala, H., Moldaver, D., Shokar, S., Ammendolea, C., Brezden-Masley, C. (2023). Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-023-07185-7
Brehaut, J. C., Carroll, K., Gordon, J., Presseau, J., Richards, D. P., Fergusson, D. A., Graham, I. D., et al. (2021). Results from a theory-guided survey to support breast cancer trial participation: Barriers, enablers, and what to do about them. Current Oncology, 28(3), 2014–2028. http://dx.doi.org/10.3390/curroncol28030187
Cardoso, F., Wilking, N., Bernardini, R., Biganzoli, L., Espin, J., Miikkulainen, K., Schuurman, S., Spence, D., Spitz, S., Ujupan, S., Zernik, N., & Gordon, J. (2020). A multi-stakeholder approach in optimising patients’ needs in the benefit assessment process of new metastatic breast cancer treatments. The Breast, 52, 78-87. https://doi.org/10.1016/j.breast.2020.04.011
Dent, S., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., Kfoury, S., et al. (2019). A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Current Oncology, 26(1), 70–80. http://dx.doi.org/10.3747/co.26.4220
PARTAGER
Nos témoignages
Inscrivez-vous dès maintenant pour recevoir des mises à jour par courriel
À propos du RCCS
Le RCCS s’efforce de faire valoir les perspectives et les préoccupations des patientes du cancer du sein en faisant de la sensibilisation, en organisant des activités de défense des intérêts et en promouvant le partage de l’information.
Réseau canadien du cancer du sein
185, rue Somerset ouest, suite 318, Ottawa, ON K2P 0J2
Tél : 613-230-3044
Sans frais : 1-800-685-8820
Écrivez-nous
